Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other research firms have also commented on MNPR. Chardan Capital restated a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a research note on Monday, March 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Monopar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $107.91.

Monopar Therapeutics Trading Up 0.1%

Shares of NASDAQ MNPR opened at $87.68 on Friday. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $105.00. The firm has a market capitalization of $587.46 million, a price-to-earnings ratio of -46.15 and a beta of 1.52. The firm has a 50 day moving average of $62.26 and a 200 day moving average of $62.13.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. Sell-side analysts predict that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Trading of Monopar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MNPR. Janus Henderson Group PLC lifted its stake in shares of Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares in the last quarter. RA Capital Management L.P. increased its stake in Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares in the last quarter. Siren L.L.C. increased its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Monopar Therapeutics during the third quarter valued at about $18,904,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.